Glaukos Submits US IDE for Clinical Study of iStent Infinite in Refractory Glaucoma

January 5, 2018: By Jon Swedien

Glaukos submitted an investigational device exemption (IDE) application to the US FDA to study its iStent Infinite Trabecular Micro-Bypass System for use in a standalone procedure to reduce elevated intraocular pressure (IOP) in refractory glaucoma patients, the San Clemente, California, company announced Jan. 3.

The iStent Infinite is made up of three heparin-coated titanium stents preloaded into an auto-injection system that allows the surgeon to inject stents around Schlemm’s canal across a span of five to six hours. Once in place, the stents are designed to lower IOP by restoring the natural outflow of aqueous humor, Glaukos said.

In the IDE application, Glaukos proposes to conduct a prospective, multi-center, single-arm clinical trial to evaluate safety and performance of the iStent Infinite in about 65 refractory subjects or subjects on maximally tolerated ocular hypotensive medications. The proposed primary endpoint is a 20 percent or greater reduction in IOP from baseline at 12 months on the same or fewer medications, Glaukos said. The company said it plans to use the trial results as the basis for seeking FDA clearance via a 510(k) submission.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023